DMC wins Radium Capital Emerging Innovator Award AT 2025 LSQ GENE AWARDS
September 12, 2025
On Friday 12 September, DMC was awarded the Radium Capital Emerging Innovator Award at the 2025 Life Sciences Queensland (LSQ) GENE Awards, held in Brisbane.
The Emerging Innovator award recognises a Queensland early-stage venture in biotech, medtech and beyond that has shown remarkable dedication and innovation in their research and development.
DMC would like to thank LSQ, Radium Capital, and the Institute for Molecular Bioscience, UQ, whose support advanced our nomination.
Congratulations to the other finalists in the category: Cool Beans Underwear Pty Ltd, Southern RNA, and Spatial Imaging Pty Ltd.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
